Drugs / Zerun HPV-9
Zerun HPV-9
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05580341 | Sep 2022 → Jun 2023 | anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia | Shanghai Zerun Biotechnology Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zerun HPV-9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05580341 ↗ |
| Known as | Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) | “Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months” NCT05580341 ↗ |
| Modality | Vaccine | “Zerun 9-valent HPV recombinant vaccine” NCT05580341 ↗ |